What is HC Wainwright’s Estimate for VYGR Q1 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Voyager Therapeutics in a research report issued on Tuesday, March 17th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.24) EPS and Q4 2027 earnings at ($0.22) EPS.

Separately, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $16.50.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $3.76 on Wednesday. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $5.55. The stock has a market cap of $224.10 million, a P/E ratio of -1.85 and a beta of 1.32. The stock has a 50-day simple moving average of $3.92 and a 200-day simple moving average of $4.19.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. The company had revenue of $13.46 million for the quarter, compared to analysts’ expectations of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently made changes to their positions in the company. EcoR1 Capital LLC increased its position in shares of Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after purchasing an additional 3,332,544 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after purchasing an additional 40,147 shares during the period. Opaleye Management Inc. purchased a new position in Voyager Therapeutics during the 4th quarter worth approximately $4,704,000. Erste Asset Management GmbH grew its stake in Voyager Therapeutics by 7.0% during the 4th quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock worth $4,718,000 after buying an additional 78,348 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after buying an additional 11,929 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Activity at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the sale, the chief executive officer directly owned 484,060 shares in the company, valued at $1,834,587.40. This trade represents a 2.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 49,783 shares of company stock valued at $188,694. Company insiders own 6.39% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.